Pulmonary Exacerbations
FDA grants brensocatib priority review for bronchiectasis
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a manufacturer-issued press release.
Study identifies subphenotypes of cystic fibrosis pulmonary exacerbations
A new study published in Annals of the American Thoracic Society highlighted subphenotypes of cystic fibrosis pulmonary exacerbations and differences in biomarker profiles, clinical presentation and outcomes.
Women with cystic fibrosis have higher rates of pulmonary exacerbations
Women with cystic fibrosis have higher rates of pulmonary exacerbations compared with men, with differences appearing early in life, researchers reported at the virtual North American Cystic Fibrosis Conference.
No lung benefit with double IV antibiotic strategy for pediatric pulmonary exacerbations
Use of two IV antipseudomonal antibiotics was not associated with improvement in clinical outcomes compared with one IV and one inhaled antibiotic in young patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection.